linjc16/ctgov huggingface dataset:
Glycemic Index Variation During Low-carbohydrate Enteral Formula With and Without Fructose in Critically Ill Patients

Study Overview
=================
Brief Summary
-----------------
Hyperglycemia is a known risk factor for mortality in critically ill patients. Most of these patients receive enteral feeding. There is controversy about ideal carbohydrate composition of these diets. The aim of this study was to compare an enteral formula with the same proportion of carbohydrates with and without fructose on blood glucose levels.

Detailed Description
-----------------
Randomized, cross-over, controlled, double-blind clinical trial without washout. Adult patients admitted to the ICU who presented capillary glycemia values> 180mg / dl with a full and exclusive enteral diet. They were randomized and observed for 4 days (2 days with each diet: with / without fructose). Capillary glycemia was measured 4 / 4h.

Official Title
-----------------
Glycemic Index Variation During Low-carbohydrate Enteral Formula With and Without Fructose in Critically Ill Patients: A Cross-over Randomized Clinical Trial

Conditions
-----------------
Critical Illness

Intervention / Treatment
-----------------
* Dietary Supplement: Enteral Formula With Fructose
* Dietary Supplement: Enteral Formula Without Fructose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critical Illness Exclusive enteral diet Enteral diet with full nutritional value Hyperglycemia ≥180 mg / dl Exclusion Criteria: Oral feeding NPT (Total or Partial Parenteral Nutrition) Patient without indication of use of study diets

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Diet 1<br>Low-carbohydrate Enteral Formula With Fructose | Dietary Supplement: Enteral Formula With Fructose<br>* Low-carbohydrate Enteral Formula With Fructose<br>|
| Active Comparator: Diet 2<br>Low-carbohydrate Enteral Formula Without Fructose | Dietary Supplement: Enteral Formula Without Fructose<br>* Low-carbohydrate Enteral Formula Without Fructose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycemic Variability | To evaluate the glycemic oscillation during the use of enteral feedings | four days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hyperglycemia, Fructose, Diabetes mellitus, Enteral Nutrition, Glycemic Variability
Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021

Study Overview
=================
Brief Summary
-----------------
The overall project aim is to study outcomes after COVID-19 and influenza hospitalisation from 2016 - 2021 by retrieving data from the main social security carriers in Austria for the years 2010-2018

Official Title
-----------------
Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021

Conditions
-----------------
Covid 19, Influenza

Intervention / Treatment
-----------------
* Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with SARS Patients with Covid-19 Patients after Covid-19 Patients with influenza Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Influenza<br> | Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza<br>* PCR or antigen test for Covid 19 or Inluenza<br>|
| Covid 19<br> | Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza<br>* PCR or antigen test for Covid 19 or Inluenza<br>|
| Control group<br>hospitalisation due to other disease (not influenza or Covid 19) | Diagnostic Test: PCR or antigen test for Covid 19 or Inluenza<br>* PCR or antigen test for Covid 19 or Inluenza<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Mortality | Overall mortality after influenza or covid-19 | 5 years | 
| age distribution | age distribution in patients with influenza or covid-19 | 5 years | 
| risk profile | risk profile (e.g. prior diseases, medication) in patients who died due to influenza or covid-19 | 5 years | 
| newly diagnosed diseases | newly diagnosed diseases after influenza or covid-19 | 5 years | 
| newly prescribed medication | newly prescribed medication after influenza or covid-19 | 5 years | 
| duration of hospitalisation or unemployability | duration of hospitalisation or unemployability after influenza or covid-19 | 5 years |
Assessment of Activity Limitation in Asthma Patients

Study Overview
=================
Brief Summary
-----------------
Limitation of activity is one of the main item used by composites scores designed to assess the level of asthma control. Since this item is systematically subjectively assessed by the patient, the investigators would like to know if these subjective data are correlated with objective data. Aims of this study are: 1) To describe what means limitation of activity for asthma patients and how they deal with; 2) To describe the objective exercise capacity and characteristics of daily activity in two situations (on exacerbation, out of an exacerbation).

Official Title
-----------------
Subjective and Objective Assessment of Activity Limitation in Asthma Patients

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Other: Assessment of activity capacities


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of asthma made by a pulmonologist. Age ≥ 18 yrs-old, < 65 yrs-old. Moderate or severe exacerbation of asthma (as defined by Reddel et al in 2009) at the time of inclusion. Exclusion Criteria: All other diseases than asthma that can affect the physical activity (e.g. orthopaedic or neuromuscular disease, cardiac or vascular disease). Pregnancy or suspicion of pregnancy at the time of inclusion. The women who become pregnant during the study period will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Exacerbated asthma patients<br> | Other: Assessment of activity capacities<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Energy expenditure (expressed in MET's) measured during an ergospirometry, at the time of an exacerbation of asthma and 6 weeks later. | One MET (Metabolic Equivalent of Task) is equal to an oxygen uptake about 3.5 ml O2/kg/min. | At the time of inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Walking distance in 6 min (expressed in meters) measured at the time of an exacerbation of asthma and 6 weeks later. |  | 6 weeks | 
| Quality of life (assessed with the Asthma Quality of Life Questionnaire) measured at the time of an exacerbation of asthma and 6 weeks later. |  | At the time of inclusion | 
| Self-assessment of activity limitation |  | 7 last days before inclusion |
Depression Amongst HIV Positive Patients in Lilongwe

Study Overview
=================
Brief Summary
-----------------
Quantitative, validated tools of depression screening will be used to collect data to determine the prevalence of depression and its association with antiretroviral (ARV) adherence amongst HIV positive patients attending ART clinic at Lighthouse Lilongwe, Malawi.

Detailed Description
-----------------
Preliminary data on prevalence and associations will be collected from 200 HIV positive adult men and women attending ART clinic at the Lighthouse in Lilongwe, Malawi. Quantitative, validated tools of depression screening will be used. A short structured demographic questionnaire will be used to collect demographic data. For depression, a Patient Health Questionnaire (PHQ) will be used while alcohol use will be assessed by Alcohol Use Disorders Identification Test (AUDIT) screening tool. The data collected will provide baseline data planning, program development and evaluation, and to promote comprehensive care provision for the people living with AIDS attending ART clinics in Malawi.

Official Title
-----------------
Prevalence of Depression Amongst HIV Positive Patients Attending ART Clinic at Lighthouse Clinic, Lilongwe

Conditions
-----------------
HIV, AIDS

Intervention / Treatment
-----------------
* Other: depression screening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and above HIV positive men and women accessing care at LH Both ART naïve and on ART Registered with LH Receiving primary care and/ or ART from LH Exclusion Criteria: Too sick to comprehend consent or requiring admission Known mentally ill patient on psychiatric drugs Less than 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients initiating ART<br>HIV positive men and women initiating ART | Other: depression screening<br>* Patient Health Questionnaire<br>|
| patients on established ART<br>HIV positive men and women on established ART | Other: depression screening<br>* Patient Health Questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of depression amongst HIV positive patients attending ART clinic at Lighthouse Lilongwe, Malawi | the survey will be administered one time | enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression, AIDS, HIV
Ligamentoplasty of Ligamentum Tere Developmental Dysplasia of the Hip

Study Overview
=================
Brief Summary
-----------------
The hip is formed by the acetabulum, the proximal femur and soft tissues joining them (capsule, teres ligament, transverse ligament and pulvinar). The acetabulum is a complex structure in the growing child. It is formed by the joined pubis, This junction is called tri radiate cartilage, which is responsible for acetabular growth. The external surface of the acetabulum is covered by a horse shoe-shaped articular cartilage. The transverse ligament joins both extremes of the articular cartilage inferiorly.

Official Title
-----------------
The Role of Ligamentoplasty of Ligamentum Tere in the Management of Developmental Dysplasia of the Hip

Conditions
-----------------
Orthopedic Disorder

Intervention / Treatment
-----------------
* Procedure: ligamentoplasty of ligamentum teres


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with Developmental dysplasia of the hip (DDH) with : Age: from 9 months -3 years old. Virgin DDH. Failed closed reduction in the management of DDH. Failed open reduction through medial approach in the management of DDH. Exclusion Criteria: • Paralytic hip dislocation . Post septic hip dislocation. Traumatic hip dislocation . Age : below 9 months or above 5 years. Refusal to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 9 Months
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ligamentoplasty of ligamentum teres<br>The patients will be examined for: Length of both lower limbs in relation to each other. Length of both lower limbs according to patient age. Presence of hump related to the outer surface of the hip Presence of pain, abnormal gait, Trendlenburg test. An addition to the steps of the open reduction, the following were done: Identification of ligamentum teres Ligamentoplasty of ligamentum teres | Procedure: ligamentoplasty of ligamentum teres<br>* An addition to the steps of the open reduction, the following were done: Identification of ligamentum teres Ligamentoplasty of ligamentum teres<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| modified Harris Hip Score | score for function of the hip | 6 months |
Morphine Analgesia in Patients With Acute Appendicitis

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate morphine effect on pain reduction and diagnostic accuracy in patients admitted to emergency ward with the diagnosis of acute appendicitis.

Detailed Description
-----------------
Analgesic administration for pain control in patients with acute abdominal pain, regarding acute appendicitis, is controversial. Despite the results previous studies indicating the safeness of analgesic use in ED for acute abdominal pain, physicians still prefer to postpone their use after performing surgical evaluations. Since many patients admitted to ED are unlikely to receive prompt surgical consultation, many of them need pain relief to prevent unnecessary suffering. On the other hand such pain relief must not interfere with the diagnosis and treatment of patients and do not cause any complications. Morphine is a common and effective analgesic which, if shown to have no effect on correct diagnosis of acute abdomen, can be used for this purpose. Thus we evaluated morphine effect on pain reduction and diagnostic accuracy in patients admitted to ED with the diagnosis of acute appendicitis.

Official Title
-----------------
Double Blind Randomized Study of Morphine Analgesia in Patients With Acute Appendicitis

Conditions
-----------------
Appendicitis

Intervention / Treatment
-----------------
* Drug: Morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical signs of acute appendicitis planned for appendectomy supposed to wait for at least 1 hour in the ED before operation Exclusion Criteria: suspicion to perforated appendicitis being under the age of 13 pregnancy (according to history and ß-HCG result) opium addiction systolic blood pressure of less than 90 mmHG known cases of chronic obstructive pulmonary disease (COPD) known sensitivity to morphine history of sickle cell disease self administration of analgesics before enrollment refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Morphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Intensity |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic Accuracy |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MORPHINE, ANALGESIA, ACUTE APPENDICITS
Fast-Track vs Conventional for UKA

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if it is possible to discharge patient undergoing a UKA 1 day postoperatively

Conditions
-----------------
Unicompartmental Knee Replacement

Intervention / Treatment
-----------------
* Procedure: Fast track vs conventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: UKA, ASA I-II Exclusion Criteria: medical history of abdominal bleeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Fast track vs conventional|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Comparative Efficacy of Lidocaine Spray Versus Vaginal Misoprostol in IUD Insertion

Study Overview
=================
Brief Summary
-----------------
the aim of the present study is to compare the safety and efficacy of lidocaine spray versus misoprostol in reducing pain during IUD insertion in adolescents and nulliparous women

Official Title
-----------------
Comparative Efficacy of Lidocaine Spray Versus Vaginal Misoprostol in Reducing Pain During IUD Insertion in Adolescents and Nulliparous Women: a Randomized Controlled Trial

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Drug: lidocaine spray
* Drug: vaginal misoprostol
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adolescent and young nulliparous women requesting IUD insertion Exclusion Criteria: multiparous women, contraindications to IUD insertion or to study drugs
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: lidocaine spray<br>four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion | Drug: lidocaine spray<br>* four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion<br>|
| Active Comparator: vaginal misoprostol<br>vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement | Drug: vaginal misoprostol<br>* vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement<br>|
| Placebo Comparator: placebo<br>vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement | Drug: placebo<br>* vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain during IUD insertion | pain during IUD insertion evaluated by visual analog scale where 0 denotes no pain and 10 cm denotes the worst pain imaginable | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration of IUD insertion | duration of IUD insertion from speculum in to speculum out | 5 minutes |
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Study Overview
=================
Brief Summary
-----------------
The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Official Title
-----------------
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Conditions
-----------------
Vascular Dementia

Intervention / Treatment
-----------------
* Drug: Rivastigmine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the ages of 50 and 85 years old Have contact with a responsible caregiver 3 or more days per week Be male or a female who is surgically sterilized or one year post menopausal Exclusion Criteria: Current diagnosis of severe or unstable cardiovascular or other diseases Current diagnosis of active, uncontrolled seizure disorder, Parkinson's disease or Alzheimer's disease

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rivastigmine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cognition from baseline at week 24 |  |  | 
| Global clinical impression of change from baseline at week 24 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in activities of daily living from baseline at week 24 |  |  | 
| Change in behavioral symptoms from baseline at week 24 |  |  | 
| Change in clinical staging from baseline at week 24 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dementia,vascular,rivastigmine,stroke,memory loss